AT1R Antibodies Overview
Full name: anti-angiotensin II type 1 receptor (AT1R) antibody, also known as AT1R‑activating antibody (AT1R‑Ab).
AT1R antibodies are autoantibodies directed against the angiotensin II type 1 receptor (AT1R). AT1R is widely expressed in the kidney, and its abnormal activation can lead to vasoconstriction, inflammation, and tissue fibrosis. AT1R antibodies can enhance angiotensin II signaling by binding to the receptor, causing podocyte damage, proteinuria, and glomerulosclerosis.
AT1R antibodies and disease tips
Risk of recurrence after transplantation:In kidney transplant patients, AT1R antibodies are an independent predictor of graft failure. About 16% of acute rejection cases cannot be explained by traditional HLA antibody testing, and AT1R antibody-positive patients have a significantly increased risk of graft loss (HR: 5.4-6.6).
Potential causes of primary FSGS:AT1R antibodies can be detected in the serum of some patients with primary FSGS, suggesting that they may be involved in the pathogenesis of the disease. AT1R antibodies synergize with circulating permeability factors (such as SUPAR, CLCF-1) and may accelerate podocyte damage and proteinuria.
Clinical significance and application
Diagnostic value:AT1R antibody detection can be used as a risk assessment indicator for FSGS patients before transplantation, especially for HLA antibody-negative patients with vascular rejection or graft dysfunction.
Treatment guidance:Therapeutic strategies targeting AT1R antibodies (such as immunoadsorption, antibody neutralizing drugs) may provide new treatment directions for FSGS patients, especially for patients who are ineffective in traditional immunosuppressive treatments.